Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neotone Radiance SPF 50+ is a topical cosmeceutical intensive protective fluid developed by ISISPHARMA for the treatment and prevention of pigmentation disorders, including melasma and facial dyspigmentation. It utilizes the patented DEPI-ACT complex, which targets multiple stages of melanogenesis through active ingredients such as diacetyl boldine (Lumiskin), pure liquorice root extract, and niacinamide. The formulation also includes fractionated melanin for blue light protection and a combination of broad-spectrum UVA/UVB solar filters. Clinical data indicates that the combination of Neotone Radiance SPF 50+ and Neotone Serum has equivalent efficacy to 4% hydroquinone cream for mild-to-moderate facial dyspigmentation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neotone Radiance SPF 50+.